HCW Biologics, a Phase 2 biotech developing novel immunotherapies for cancer, filed on Wednesday with the SEC to raise up to $50 million in an initial public offering.
HCW is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. Its gateway indication is oncology, and it expects to have four active trials to evaluate its molecules for cancer indications by the end of 2021. The company's molecule HCW9201 is currently being evaluated for generation of memory-like NK cell products in two ongoing Phase 2 trials for relapsed/refractory acute myeloid leukemia, with preliminary data expected in the 2H21.
The Miramar, FL-based company was founded in 2018 and plans to list on the Nasdaq under the symbol HCWB. Kingswood Capital Markets is the sole bookrunner on the deal. No pricing terms were disclosed.
